Results 51 to 60 of about 15,553 (191)

The Evaluation of Machine Learning Models Using Matrix‐Assisted Laser Desorption/Ionization Time‐of‐Flight Mass Spectrometry (MALDI–TOF–MS) Spectra for the Prediction of Antibiotic Resistance in Klebsiella pneumoniae

open access: yesMicrobiologyOpen, Volume 15, Issue 2, April 2026.
Machine learning models developed from matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry spectra can rapidly predict antimicrobial resistance in Klebsiella pneumoniae. By transforming routine spectral data into accurate resistance profiles within minutes, this approach could reduce diagnostic delays and support earlier ...
Stephen Mark Edward Fordham
wiley   +1 more source

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

open access: yes, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A   +6 more
core   +1 more source

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

open access: yesmBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai   +10 more
doaj   +1 more source

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

open access: yesMicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston   +8 more
wiley   +1 more source

Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health" Approach. [PDF]

open access: yes, 2019
Treating infection is a key part of the work of most clinicians [...]
Lipman, J, Lonsdale, DO
core   +1 more source

Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.

open access: yesPLoS ONE, 2021
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) poses a major threat to human health worldwide. Combination therapies of antibiotics with different mechanisms have been recommended in literatures.
Fangzhou Wang   +4 more
doaj   +1 more source

Bacteriophage Therapy: Current Strategies and Future Perspectives

open access: yesMedComm, Volume 7, Issue 3, March 2026.
This manuscript systematically reviews the expanding scope of phage applications. It moves beyond traditional antibacterial use to explore their role in precision therapies against drug‐resistant infections, their synergy with antibiotics, and advanced biomaterial‐assisted delivery systems.
Zihe Zhou   +7 more
wiley   +1 more source

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. [PDF]

open access: yes, 2016
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an ...
Armstrong, Jon   +15 more
core  

Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]

open access: yes, 2015
Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M.   +3 more
core   +1 more source

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

open access: yesAntibiotics, 2021
Stenotrophomonas maltophilia is an urgent global threat due to its increasing incidence and intrinsic antibiotic resistance. Antibiotic development has focused on carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter, with approved ...
Jean Gibb, Darren W. Wong
doaj   +1 more source

Home - About - Disclaimer - Privacy